| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99347 |
|
623 |
546 |
$13K |
| M0221 |
Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency |
21 |
21 |
$5K |
| 99334 |
|
30 |
30 |
$834.89 |
| 99325 |
|
24 |
24 |
$354.37 |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
19 |
19 |
$75.27 |
| 99309 |
Subsequent nursing facility care, per day, low to moderate complexity |
54 |
33 |
$38.78 |
| 90792 |
Psychiatric diagnostic evaluation with medical services |
65 |
35 |
$0.00 |
| 99402 |
|
19 |
19 |
$0.00 |